Apyx Medical Inc (APYX) FinancialsAPYXApyx Medical Inc

Apyx Medical Inc (APYX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical Aesthetics, accounting for 85.9% of total sales, equivalent to $10.73M. Another important revenue stream is OEM. Understanding this composition is critical for investors evaluating how APYX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Apyx Medical Inc maintains a gross margin of 63.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13.01%, while the net margin is -22.13%. These profitability ratios, combined with a Return on Equity (ROE) of -96.38%, provide a clear picture of how effectively APYX converts its operational activities into shareholder value.

In the context of the broader market, APYX competes directly with industry leaders such as ORGO and KEQU. With a market capitalization of $128.89M, it holds a leading position in the sector. When comparing efficiency, APYX's gross margin of 63.89% stands against ORGO's 45.90% and KEQU's 29.61%. Such benchmarking helps identify whether Apyx Medical Inc is trading at a premium or discount relative to its financial performance.

Apyx Medical's revenue has shown growth, with Q1 2026 revenue reported at $12.5 million, a 33% increase year-over-year. The gross margin remains strong at approximately 63% for recent quarters, indicating effective cost management despite ongoing losses. However, the company has reported negative net income consistently, with a Q2 2026 net income of -$3.24 million.